We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.165 | -0.38% | 43.825 | 44.62 | 43.78 | 44.16 | 6,209,390 | 20:33:05 |
Bristol-Myers Squibb Co. said Thursday it plans to close two sites, eliminate 100 positions and discontinue discovery-research efforts in virology while it makes adjustments for other expansions in research and development.
Bristol said it plans to close its Waltham, Mass., and Wallingford, Conn., sites and open a new facility in Cambridge, Mass., in early 2018. Its ongoing expansion in the San Francisco Bay is expected to be completed next year.
The company said its decision to discontinue discovery research in virology wouldn't impact marketed virology products like the medicines Baraclude, Reyataz, Evotaz, Sustiva and Sunvepra. About 100 discovery positions will be eliminated in connection with the changes to Bristol's R&D focus.
Bristol-Myers said it would continue to focus on research in immuno-oncology as well as heart failure, fibrosis, genetically defined diseases and immunoscience.
In March, the company received U.S. Food and Drug Administration approval for Opdivo as a lung cancer drug.
Shares of Bristol, up 35% in the last 12 months, ticked up 0.8% to $67.33 a share in midday trading.
Write to Cassandra Jaramillo at cassandra.jaramillo@wsj.com
Access Investor Kit for Bristol-Myers Squibb Co.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US1101221083
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions